Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479650 | 0.85 | CA1 (0.72) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11948472 | 0.83 | CA1 (0.38) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29645438 | 0.83 | CA1 (0.38) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28795709 | 0.79 | CA12 (0.31) | CA1CA2CA7CA9CA12 | |
| SCHEMBL20385155 | 0.78 | — | — | |
| SCHEMBL8191834 | 0.78 | — | — | |
| SCHEMBL21364247 | 0.78 | — | — | |
| SCHEMBL4317437 | 0.78 | — | — | |
| SCHEMBL17364483 | 0.77 | TSHR (0.52) | ALDH1A1TSHRHTTMAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31501476 | 0.76 | TSHR (0.46) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518368-B2 | Method for the production of hydrogen from ammonia borane | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110070152-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| EP-2158154-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | Kanata Chemical Technologies Inc. (CA) | 2010-03-03 | — | — | EP | disclosed |
| US-20090137687-A1 | Compositions and Methods With Enhanced Therapeutic Activity | OXIGENE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137687-A1 | Compositions and Methods With Enhanced Therapeutic Activity | OXIGENE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2008141439-A1 | METHOD FOR THE PRODUCTION OF HYDROGEN FROM AMMONIA BORANE | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137687-A1 | Compositions and Methods With Enhanced Therapeutic Activity | NQO1, MKI67, COMT | CA1 1191/4885CA2 640/4885CA7 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.